2-Monoacylglycerol Mimetic Liposomes to Promote Intestinal Lymphatic Transport for Improving Oral Bioavailability of Dihydroartemisinin
DOI: https://doi.org/10.2147/ijn.s462374
IF: 7.033
2024-06-07
International Journal of Nanomedicine
Abstract:Bin Zheng, 1– 3, &ast Fei Pan, 1– 3, &ast Minfei Shi, 1– 3 Cuiping He, 1– 3 Beibei He, 1– 3 Rongrong Wang, 1– 3 Guolian Ren, 1– 3 Shuang Yang, 4 Shuqiu Zhang 1– 3 1 School of Pharmacy, Shanxi Medical University, Taiyuan, 030001, People's Republic of China; 2 Medicinal Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical University, Taiyuan, 030001, People's Republic of China; 3 Shanxi Provincial Key Laboratory of Drug Synthesis and Novel Pharmaceutical Preparation Technology, Shanxi Medical University, Taiyuan, 030001, People's Republic of China; 4 School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shuang Yang, School of Basic Medical Sciences, Shanxi Medical University, No. 56, Xinjian South Road, Taiyuan, 030001, People's Republic of China, Email Shuqiu Zhang, School of Pharmacy, Shanxi Medical University, No. 56, Xinjian South Road, Taiyuan, 030001, People's Republic of China, Email Purpose: Reducing the first-pass hepatic effect via intestinal lymphatic transport is an effective way to increase the oral absorption of drugs. 2-Monoacylglycerol (2-MAG) as a primary digestive product of dietary lipids triglyceride, can be assembled in chylomicrons and then transported from the intestine into the lymphatic system. Herein, we propose a biomimetic strategy and report a 2-MAG mimetic nanocarrier to target the intestinal lymphatic system via the lipid absorption pathway and improve oral bioavailability. Methods: The 2-MAG mimetic liposomes were designed by covalently bonding serinol (SER) on the surface of liposomes named SER-LPs to simulate the structure of 2-MAG. Dihydroartemisinin (DHA) was chosen as the model drug because of its disadvantages such as poor solubility and high first-pass effect. The endocytosis and exocytosis mechanisms were investigated in Caco-2 cells and Caco-2 cell monolayers. The capacity of intestinal lymphatic transport was evaluated by ex vivo biodistribution and in vivo pharmacokinetic experiments. Results: DHA loaded SER-LPs (SER-LPs-DHA) had a particle size of 70 nm and a desirable entrapment efficiency of 93%. SER-LPs showed sustained release for DHA in the simulated gastrointestinal environment. In vitro cell studies demonstrated that the cellular uptake of SER-LPs primarily relied on the caveolae- rather than clathrin-mediated endocytosis pathway and preferred to integrate into the chylomicron assembly process through the endoplasmic reticulum/Golgi apparatus route. After oral administration, SER-LPs efficiently promoted drug accumulation in mesenteric lymphatic nodes. The oral bioavailability of DHA from SER-LPs was 10.40-fold and 1.17-fold larger than that of free DHA and unmodified liposomes at the same dose, respectively. Conclusion: SER-LPs improved oral bioavailability through efficient intestinal lymphatic transport. These findings of the current study provide a good alternative strategy for oral delivery of drugs with high first-pass hepatic metabolism. Keywords: intestinal lymphatic transport, biomimetic liposomes, first-pass hepatic metabolism, oral delivery, dihydroartemisinin Graphical Oral delivery is the most common and acceptable administration for patients and thus has a high market share. 1–3 However, a majority of oral drugs show low bioavailability due to their low solubility in gastrointestinal (GI) fluids, degradation by strong acids and enzymes in the GI tract, poor absorption by intestinal epithelial cells, and first-pass hepatic metabolism. 4–7 A typical example is dihydroartemisinin (DHA), the first-line drug used for the treatment of malaria in the clinic. 8 Recently, numerous literature reports have emerged that DHA possesses the potential to become a new generation of drugs for treating systemic lupus erythematosus. 9–11 In addition to its prominent antimalarial and immunoregulatory effects, DHA has been reported to have effective anticancer activity. 12–16 However, concerning the oral administration of DHA, there remains a critical challenge in the low oral bioavailability due to the reasons of poor water solubility and extremely high first-pass effect. 17–19 It is widely known that oral drugs can be transported in systemic circulation by either the portal vein or the intestinal lymphatic system. After transport across the enterocyte, the majority of drugs (including DHA) prefer to enter the liver via the hepatic portal vein pathway and are then metaboliz -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology